• Metabolon

  Participated · Series E · Jan 2014

  Metabolon provides metabolomics and lipidomics solutions that support life‑science research, diagnostics, therapeutic development, and precision medicine applications. Its platform includes a Global Discovery Panel enabled by a proprietary metabolomics reference library and scalable, customizable multiomics offerings that span discovery through clinical trials and product life‑cycle management. The company cites more than 20 years of activity, 10,000+ projects, and 3,000+ publications, and holds ISO 9001:2015, CLIA, and CAP certifications. Led by CEO Rohan (Ro) Hastie and based in Morrisville, NC, Metabolon positions itself as a global leader in metabolomics. The company intends to use recent financing to enhance growth initiatives, expand research and development, and further develop its metabolomics platform. It also plans to support global expansion, market penetration initiatives, and strategic partnerships. Metabolon is a Morrisville, NC-based provider of scalable, customizable metabolomics and lipidomics solutions supporting customer needs from discovery through clinical trials and product life-cycle management. Led by CEO Rohan (Ro) Hastie, the company serves research, diagnostic, therapeutic development, and precision medicine applications. Its offerings include a Global Discovery Panel enabled by a proprietary metabolomics reference library and scientific, technology, and bioinformatics techniques developed over more than 20 years. Metabolon reports completing 10,000+ projects and being cited in over 3,000 publications, and holds ISO 9001:2015 and CLIA certifications. The company recently raised $25M and intends to use the funds to accelerate commercialization activities and continue advancing its R&D roadmap. Metabolon provides scalable, customizable metabolomics solutions from discovery through clinical trials and product life-cycle management using its Precision Metabolomics™ Platform and proprietary reference library. Over more than 20 years the company has completed 10,000+ projects and contributed to 2,000+ publications, and holds ISO 9001:2015 and CLIA certifications. Its technology deciphers thousands of discrete chemical signals to reveal biological pathways and phenotype-level insights that other 'omics cannot. The company recently closed a $72 million combined debt and equity financing to support growth. Management says the incremental funding will accelerate growth, expand the client base, and fund R&D programs in machine learning for novel biomarker discovery and to expand its precision medicine platform. Metabolon also announced the appointment of Robert A. Cascella to its board alongside independent members Todd Schermerhorn and Jan Lundberg. Metabolon develops proprietary metabolomics platforms and informatics to deliver biomarker discoveries, diagnostic tests, and precision medicine products. The company plans to use the financing proceeds to further develop and commercialize its pipeline of precision medicine offerings based on its metabolomics technology. Metabolon serves clients across pharmaceutical, biotechnology, consumer products, agriculture, nutrition, academic, and government sectors. It has conducted more than 5,000 independent and collaborative studies and has over 600 peer-reviewed publications. Founded in 2000 and led by president and CEO John Ryals, Ph.D., the company is based in Research Triangle Park, N.C. Financially, Metabolon has raised approximately $80M to date and closed a new financing to support its commercialization efforts. Metabolon is a metabolomics firm in the precision medicine space that develops phenotyping technology to determine individual drug metabolism and response. Its core product uses metabolomics profiling to inform drug-response and precision-treatment decisions. The company announced a collaboration last year with Human Longevity Inc. According to a Wall Street Journal report, Metabolon generated about $25 million in revenue last year. It has been backed by roughly $50 million in private funding from investors including Aurora Funds Inc., Fletcher Spaght Ventures LP, Syngenta Ventures, Sevin Rosen Funds, Harris & Harris Group Inc., and Keating Capital Inc. Company representatives had not provided details on how the new funding will be used.

• Argos Therapeutics

  Participated · Series E · Nov 2013

  Argos Therapeutics focuses on the development and commercialization of individualized immunotherapies for cancer and infectious diseases. Its most advanced product, Rocapuldencel-T, is being evaluated in a clinical trial for metastatic renal cell carcinoma. The company has a partnership with Hong Kong firm Lummy for Rocapuldencel-T in China and other territories. Argos has faced financial pressure: its stock fell 65 percent in one day in February 2017 and the company has not received FDA approval for any drug since its establishment in 1997. In November 2017 Argos received $1.8 million from TKC Properties selling a building that housed one of the company’s facilities, funds the company said will allow it to last through June. At the time of the filing its stock traded around 16–17 cents per share. Argos Therapeutics develops fully personalized immunotherapies via its Arcelis™ technology, which captures mutated and variant antigens specific to each patient’s disease and is aimed at multiple cancers and infectious diseases. The company’s lead candidate, AGS-003, has initiated a pivotal Phase 3 ADAPT trial for metastatic renal cell carcinoma (mRCC). Argos recently raised additional funding to support that trial and to advance its clinical programs. The company raised an additional $17.5M in Series E financing, bringing total committed Series E funds to $60M. Argos is led by president and CEO Jeff Abbey and is based in Durham, North Carolina. Its AGS-004 candidate recently completed enrollment of a Phase 2b study for HIV. Argos Therapeutics leverages its Arcelis technology platform to develop personalized immunotherapies for the treatment of cancer and infectious diseases. Its lead product candidate, AGS-003, has initiated a pivotal Phase 3 study for metastatic renal cell carcinoma (mRCC). The company also develops AGS-004 for the treatment of HIV and expects Phase 2b data in the first half of 2014. Argos intends to use proceeds from the financing to support the Phase 3 clinical study of AGS-003. In August 2013 the company secured $42.5M in Series E financing, providing near-term capital to advance its clinical programs. Jeff Abbey serves as President and Chief Executive Officer. Argos Therapeutics is a Durham, North Carolina-based biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies using its Arcelis™ technology platform. The Arcelis platform uses biological components from each patient and employs the patient’s dendritic cells to activate an immune response specific to the patient’s disease. The company’s most advanced product candidates are AGS-003 for metastatic renal cell carcinoma (mRCC) and AGS-004 for HIV. Research and development are led by Charles Nicolette, Ph.D., chief scientific officer and vice president of R&D. Argos raised $25M in a Series D financing and intends to use the proceeds to support the planned commencement of its Phase 3 ADAPT study in newly diagnosed mRCC patients in mid-2012.

• Regado Biosciences

  Participated · Series E · Dec 2012

  Regado Biosciences develops antithrombotic aptamers paired with active control agents, including clinical candidates REG1 and REG3. The company is advancing REG1 toward a Phase 3 study called REGULATE – PCI for use in percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) population. It is also pursuing a parallel development program of REG1 for transaortic valve implantation (TAVI) and a program for REG3 in diabetic vasculopathy. Regado recently secured $51m in Series E financing to support these programs. The company is led by President and CEO David J. Mazzo, PhD, and is based in Basking Ridge, New Jersey, with a lab facility in Durham, North Carolina. Regado Biosciences, based in Basking Ridge, NJ, focuses on a new therapeutic technology applied to injectable antithrombotics. The company is developing a pipeline of programs targeting arterial and venous thrombosis. It is also working to identify therapeutic aptamers as clinical candidates. Regado completed a $40M Series D financing to support these efforts. The round was led by Edmond de Rothschild Investment Partners (part of The LCF Rothschild Group) and included participation from Domain Associates, Quaker Bioventures, Aurora Funds, Caxton Advantage Life Sciences Fund and other individual investors. Proceeds will be used to continue development of its thrombosis programs and to advance identification of a clinical aptamer candidate.

• Cardioxyl Pharmaceuticals

  Participated · Series B · Nov 2012

  Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery and development of new classes of therapeutic agents for cardiovascular disease. The company’s core HNO (nitroxyl) platform has produced several pre-clinical and clinical candidates. Cardioxyl is advancing second-generation HNO donor programs intended to treat acute and chronic heart failure. The company is led by President and CEO Chris Kroeger, M.D. It intends to use newly raised capital to further advance those second-generation HNO programs. Cardioxyl is based in Chapel Hill, North Carolina. Cardioxyl Pharmaceuticals is a clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease. The company is based in Chapel Hill, NC. Its lead drug candidate is CXL-1020, being developed for acute decompensated heart failure (ADHF). Cardioxyl reported positive safety and tolerability results in the first clinical study of CXL-1020. The company raised an additional $15 million to execute a Phase IIa trial of CXL-1020 and to continue development of its research portfolio. Investors in the funding include existing backers Aurora Funds and New Enterprise Associates (NEA).

• Digitalsmiths

  Participated · Series C · Apr 2011

  Digitalsmiths builds video search and discovery products that generate comprehensive, accurate and actionable video metadata to enable personalized experiences across devices. Its solutions are content-format and device-agnostic and are used by studios, broadcasters and distributors such as Warner Bros., Turner, The CW Network, Paramount and Telepictures. The company highlights real-time capabilities — for example, a partnership with Turner Sports enabled fans to search and watch NCAA March Madness highlights in real time and target those videos with ads. Digitalsmiths says its products unlock new monetization streams for content owners and operators through improved discovery and targeted advertising. To accelerate domestic and international sales and expand its product roster and patent portfolio, the company closed an oversubscribed $12.5 million expansion financing. Digitalsmiths also acquired competitor Gotuit earlier in the year to extend its market position. Digitalsmiths provides a video indexing and ad-targeting platform that analyzes visual and audio content to enable search and thematic ad placement. The company has been indexing digital video content for Hollywood studios for the past three years and recently began offering its technology to web-based video platforms. Its product aims to help content owners and publishers monetize video more efficiently while enabling advertisers to target ads to thematically relevant content automatically. Notable deployments include Warner Bros.' use on TheWB.com for searchable clip archives and adoption by TMZ, which replaced Brightcove with Digitalsmiths. The company competes with players such as Auditude and Viewdle. Digitalsmiths recently closed a $12 million Series B to extend its platform.

No current team members are available.